Survival of Trial-Like and Non-Trial-Like Patients With Immunotherapy in Advanced Hepatocellular Carcinoma in Real World: A Collaborative Multicenter Indian Study (IMHEP).
Anant RamaswamyAnand V KulkarniGeorge JohnAmit RauthanShekhar PatilAjay Kumar DusejaVineet TalwarSenthil J RajappaNikhil GhadyalpatilManav WadhawanAkash ShuklaVamshi M KrishnaSujay SrinivasSunil TanejaK Mary SravaniSahaj RathiPrabhat BhargavaVikas OstwalPublished in: JCO global oncology (2023)
Patients with advanced HCC in the real world, trial-like have survivals in consonance with trial data, whereas patients with features excluding them from trials, such as main portal vein thrombosis, poor ECOG PS, and child Pugh B status, have markedly inferior survivals, despite good tolerance to immunotherapy.